
Diagnostic and prognostic significance of lncRNA THRIL in gestational diabetes mellitus and the regulation of trophoblastic function
Brief intro:
- Author: Jian Li, Shihui Hao & Mengjie Chen
- Journal: Irish Journal of Medical Science (1971 -)
- Doi: https://www.doi.org/10.1007/s11845-025-04067-3
- Publication Date: 2025/8/11
Abstract
Background: Gestational diabetes mellitus (GDM), a common rising pregnancy complications, seriously affects maternal and infant prognosis. Objectives: This study analyzed the clinical significance of THRIL in GDM patients, as well as explored the potential mechanism by which THRIL regulated the GDM progression through miR-424. Methods: RT-qPCR detected THRIL and miR-424 levels. ROC and logistic regression analyzed diagnostic and predictive significance of THRIL. The dual luciferase assay verified the negative regulatory relationship between THRIL and miR-424. The HTR-8/SVneo high-glucose (HG) injury model was established, and the effects of THRIL overexpression as well as co-overexpression of THRIL and miR-424 on cell behavior were detected using CCK-8, flow cytometry, and Transwell assays. Results: THRIL was decreased in serum of GDM patients (P < 0.001), while miR-424 was elevated (P < 0.001), and the two were negatively regulated by each other (r = -0.70, P < 0.01). Serum THRIL had a strong ability to recognize GDM (AUC = 0.92, P < 0.01) and predicted the occurrence of adverse pregnancy outcomes (OR = 12.860, P < 0.001). In the HTR-8/SVneo HG induction model, THRIL overexpression significantly promoted cell proliferation, migration, and invasion, and inhibited apoptosis (P < 0.01). While THRIL and miR-424 co-overexpression effectively eliminated the positive effect of THRIL overexpression on cell behavior (P < 0.01). Conclusion: The down-regulated THRIL inhibits the behavior of trophoblast cells through miR-424, thereby affecting pregnancy outcomes in GDM patients. Serum THRIL is a promising marker for the diagnosis and prediction of GDM.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
